Journal
MEDICINE
Volume 100, Issue 5, Pages -Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MD.0000000000024275
Keywords
hemodialysis; high mobility group box protein-1; peritoneal dialysis; prognosis
Categories
Ask authors/readers for more resources
This study found that the HMGB1 levels in HD patients are higher than in PD patients, and the levels decrease with HD or PD treatment and are positively correlated with IL-6 and TNF-alpha. Patients with higher HMGB1 levels had more complications but no difference in survival rates. Quality of life was associated with different dialysis methods.
To investigate serum level of high mobility group box protein-1 (HMGB1) and prognosis of patients with end-stage renal disease (ESRD) on hemodialysis (HD) and peritoneal dialysis (PD). This prospective cohort observational study included a total of 253 ESRD patients who came to our hospital for HD or PD from February 2013 to February 2015. Enzyme linked immunosorbent assay (ELISA) method was used to detect the serum level of HMGB1, interleukin (IL-6), IL-8, and tumor necrosis factor-alpha (TNF-alpha). The kidney disease quality of life short form (KDQOL-SF) and kidney disease targeted area (KDTA) was applied for evaluating the quality of life. Kaplan-Meier (K-M) curve was performed for survival time. Serum level of HMGB1 in patients on HD was higher than PD. HMGB1 levels were gradually decreased with the treatment of HD or PD. Furthermore, HMGB1 was positively correlated with IL-6 and TNF-alpha. Moreover, patients with higher HMGB1 had more complications than patients with lower HMGB1, but there was no difference for the survival rate. In addition, the quality of life was associated with different dialysis methods. The serum level of HMGB1 and prognosis of ESRD patients was associated with different dialysis methods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available